

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580

Final Stakeholder List


Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Company Pharmanovia (catumaxomab) Patient/carer groups AMEND AMMF – The Cholangiocarcinoma Charity Black Health Agency for Equality Bob Champion Cancer Trust Bowel Cancer UK Breast Cancer Now Breast Cancer UK British Liver Trust Butterfly Thyroid Cancer Trust Cancer Black Care Cancer Black Care Cancer52 Eve Appeal Fight Bladder Cancer GIST Cancer UK Go Girls Guts UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Inflammatory Breast Cancer Network UK Liver4Life LIVErNORTH Lobular Breast Cancer Macmillan Cancer Support Maggie's Centres Marie Curie METUPUK OG Support 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government Comparator companies None Relevant research groups Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

Final stakeholder list for the evaluation of catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Oncogene-Driven Lung Cancer Patient Alliance UK OPA Cancer Charity Oesophageal and Gastric Support Oncogene Cancer Research Orchid Ovacome Ovarian Cancer Action Pancreatic Cancer Action Pancreatic Cancer UK PCaSO Prostate Cancer Support Organisation Pelican Cancer Foundation Prevent Breast Cancer Prostate Cancer Research Prostate Matters Robin Cancer Trust Roy Casle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tackle Prostate Cancer Target Ovarian Cancer Tenovus Cancer Care United Kingdom Lung Cancer Coalition 	
 Healthcare professional groups Association of Cancer Physicians British Geriatrics Society British Oncology Pharmacy Association British Psychosocial Oncology Society Cancer Research UK Cholangiocarcinoma UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Oncology Nursing Society 	

Final stakeholder list for the evaluation of catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators


Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Final stakeholder list for the evaluation of catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580

Issue date: October 2025





Final stakeholder list for the evaluation of catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580